151 related articles for article (PubMed ID: 11575485)
1. Cost-effectiveness of harm reduction in preventing hepatitis C among injection drug users.
Pollack HA
Med Decis Making; 2001; 21(5):357-67. PubMed ID: 11575485
[TBL] [Abstract][Full Text] [Related]
2. Estimation of the number of injecting drug users attending an outreach syringe-exchange program and infection with human immunodeficiency virus (HIV) and hepatitis C virus: the AjUDE-Brasil project.
Caiaffa WT; Mingoti SA; Proietti FA; Carneiro-Proietti AB; Silva RC; Lopes AC; Doneda D
J Urban Health; 2003 Mar; 80(1):106-14. PubMed ID: 12612100
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
[No Abstract] [Full Text] [Related]
4. Estimating the cost-effectiveness of needle-syringe programs in Australia.
Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
[TBL] [Abstract][Full Text] [Related]
5. Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18-30 years, 1994-2004.
Burt RD; Hagan H; Garfein RS; Sabin K; Weinbaum C; Thiede H
J Urban Health; 2007 May; 84(3):436-54. PubMed ID: 17356901
[TBL] [Abstract][Full Text] [Related]
6. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
[TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of HCV and HIV infection among clients of the nation's longest-standing statewide syringe exchange program: A cross-sectional study of Community Health Outreach Work to Prevent AIDS (CHOW).
Salek TP; Katz AR; Lenze SM; Lusk HM; Li D; Des Jarlais DC
Int J Drug Policy; 2017 Oct; 48():34-43. PubMed ID: 28779632
[TBL] [Abstract][Full Text] [Related]
8. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews.
Palmateer N; Kimber J; Hickman M; Hutchinson S; Rhodes T; Goldberg D
Addiction; 2010 May; 105(5):844-59. PubMed ID: 20219055
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of harm reduction programs on seroincidence of HIV, hepatitis B and C, and syphilis among intravenous drug users in southwest China.
Ruan Y; Liang S; Zhu J; Li X; Pan SW; Liu Q; Song B; Wang Q; Xing H; Shao Y
Sex Transm Dis; 2013 Apr; 40(4):323-8. PubMed ID: 23486498
[TBL] [Abstract][Full Text] [Related]
10. [The efficacy of needle exchange programs in the prevention of HIV and hepatitis infection among injecting drug users].
Takács IG; Demetrovics Z
Psychiatr Hung; 2009; 24(4):264-81. PubMed ID: 19949245
[TBL] [Abstract][Full Text] [Related]
11. Socio-behavioral and geographic correlates of prevalent hepatitis C virus infection among young injection drug users in metropolitan Baltimore and Chicago.
Boodram B; Golub ET; Ouellet LJ
Drug Alcohol Depend; 2010 Sep; 111(1-2):136-45. PubMed ID: 20472373
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004.
Falster K; Kaldor JM; Maher L;
J Urban Health; 2009 Jan; 86(1):106-18. PubMed ID: 18979201
[TBL] [Abstract][Full Text] [Related]
13. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.
Emmanuelli J; Desenclos JC
Addiction; 2005 Nov; 100(11):1690-700. PubMed ID: 16277629
[TBL] [Abstract][Full Text] [Related]
14. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004.
Holtzman D; Barry V; Ouellet LJ; Des Jarlais DC; Vlahov D; Golub ET; Hudson SM; Garfein RS
Prev Med; 2009 Aug; 49(1):68-73. PubMed ID: 19410600
[TBL] [Abstract][Full Text] [Related]
15. Needle exchange use, sexual risk behaviour, and the prevalence of HIV, hepatitis B virus, and hepatitis C virus infections among Bulgarian injection drug users.
Vassilev ZP; Hagan H; Lyubenova A; Tomov N; Vasilev G; Krasteva D; Des Jarlais DC
Int J STD AIDS; 2006 Sep; 17(9):621-6. PubMed ID: 16942654
[TBL] [Abstract][Full Text] [Related]
16. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study.
Ruan Y; Qin G; Yin L; Chen K; Qian HZ; Hao C; Liang S; Zhu J; Xing H; Hong K; Shao Y
AIDS; 2007 Dec; 21 Suppl 8():S39-46. PubMed ID: 18172390
[TBL] [Abstract][Full Text] [Related]
17. The association between law enforcement encounters and syringe sharing among IDUs on skid row: a mixed methods analysis.
Wagner KD; Simon-Freeman R; Bluthenthal RN
AIDS Behav; 2013 Oct; 17(8):2637-43. PubMed ID: 23620243
[TBL] [Abstract][Full Text] [Related]
18. Optimal provision of needle and syringe programmes for injecting drug users: A systematic review.
Jones L; Pickering L; Sumnall H; McVeigh J; Bellis MA
Int J Drug Policy; 2010 Sep; 21(5):335-42. PubMed ID: 20189375
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high.
Goldberg D; Cameron S; McMenamin J
Commun Dis Public Health; 1998 Jun; 1(2):95-7. PubMed ID: 9644121
[TBL] [Abstract][Full Text] [Related]
20. Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010.
Wiessing L; Likatavicius G; Hedrich D; Guarita B; van de Laar MJ; Vicente J
Euro Surveill; 2011 Dec; 16(48):. PubMed ID: 22172300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
